Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Leqvio®-siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03851705 ORION-5 (CKJX839A12302) Hypercholesterolemia inc. Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 56 LDL-C reduction at Day 150 Changes in PCSK9, other lipids and lipoproteins Part 1: inclisiran sodium 300mg on Day 1 and Day 90 or placebo on Day 1 and Day 90 Part 2: inclisiran sodium 300mg on Day 180 for patients who were randomized to the placebo group only, inclisiran sodium 300mg on Day 270 and then every 6 months for a planned duration of 2 years for all patients Patients with HoFH with background statin +/- ezetimibe therapy NCT04652726 ORION-16 (CKJX839C12301) Hyperlipidemia, pediatrics Phase 3 150 Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630; Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL- Primary: Q3-2020 (actual); Final: H2-2021 Read-out Milesstone(s) Publication TBD 65 Investor Relations | Q3 2021 Results 2023 TBD NOVARTIS | Reimagining Medicine

View entire presentation